分析 1992 年至 2011 年期间中国颁发的抗生素专利。

The General Hospital of Shenyang Military Region, Department of Respiratory Medicine, Shenyang, Liaoning 110840, China.

Expert Opin Ther Pat. 2012 Oct;22(10):1205-32. doi: 10.1517/13543776.2012.722204. Epub 2012 Sep 7.

INTRODUCTION

The wide use of antibiotics both within and beyond the medical territory plays a significant role in the development of resistant bacteria. Therefore, there is a pressing need for the development of effective antibiotics worldwide.

AREAS COVERED

The current analysis report covers the scientific progress in supporting antibiotic patent application and the granted patent literature in China for the last 20 years.

EXPERT OPINION

Among the 2780 patents granted in China last 20 years, β-lactam antibiotics, macrolides, quinolones, aminoglycosides, sulfonamides, glycopeptides and tetracyclines constitute 44.3, 17.4, 13.5, 4.1, 3.8, 3.0 and 2.1% of total patents, respectively. Scientists have faced challenges in developing new antibiotics against increasingly growing types of drug-resistant bacteria, which may causes serious global public health disaster in future. Poor financial investment in antibiotic research has exacerbated the situation. Therefore, new antibiotic patents will be applied continuously. The combination individual β-lactam antibiotics with a β-lactamase inhibitor have been demonstrated clinically beneficial and may suggest a new way for the development of more effective antibiotics in future. Local patent applications of China are stably increasing largely through a dependence on the imitation of Western drugs. The current study may help to better understand the patent situation in China and to invent the more efficient antibiotic therapies.

简介

抗生素在医学领域内外的广泛使用是耐药菌发展的重要原因。因此，全球迫切需要开发有效的抗生素。

涵盖领域

本分析报告涵盖了过去 20 年来支持抗生素专利申请和已授予专利文献的科学进展。

专家意见

在过去 20 年中国授予的 2780 项专利中，β-内酰胺类抗生素、大环内酯类、喹诺酮类、氨基糖苷类、磺胺类、糖肽类和四环素类分别占总专利的 44.3%、17.4%、13.5%、4.1%、3.8%、3.0%和 2.1%。科学家们在开发针对日益增长的耐药菌类型的新型抗生素方面面临挑战，这可能在未来引发严重的全球公共卫生灾难。对抗生素研究的财政投入不足使情况恶化。因此，将不断申请新的抗生素专利。β-内酰胺类抗生素与β-内酰胺酶抑制剂联合使用已被证明具有临床益处，这可能为未来开发更有效的抗生素提供新途径。中国的本地专利申请主要通过依赖仿制西药而稳定增长。本研究可能有助于更好地了解中国的专利情况，并发明更有效的抗生素疗法。